Issue 9, 2021

Retraction: MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells

Abstract

Retraction of ‘MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells’ by Guimin Chen et al., RSC Adv., 2019, 9, 21139–21146, DOI: 10.1039/C8RA10224D.

Associated articles

Article information

Article type
Retraction
Submitted
19 Jan 2021
Accepted
19 Jan 2021
First published
27 Jan 2021
This article is Open Access
Creative Commons BY license

RSC Adv., 2021,11, 5265-5265

Retraction: MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells

L. Fisher, RSC Adv., 2021, 11, 5265 DOI: 10.1039/D1RA90049H

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements